<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAKENA- hydroxyprogesterone caproate injection </strong><br>Lumara Health Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MAKENA safely and
        effectively. See full prescribing information for MAKENA.<br><br> MAKENA®
        (hydroxyprogesterone caproate injection) for intramuscular use. <br>Initial U.S. Approval:
        1956</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Makena is a progestin indicated to reduce the risk of
                                    preterm birth in women with a singleton pregnancy who have a
                                    history of singleton spontaneous preterm birth. </p>
<p class="Highlighta"><span class="Bold"><span class="Underline">Limitation of use</span>: Makena is not intended for
                                        use in women with <span class="product-label-link" type="condition" conceptid="432969" conceptname="Multiple pregnancy">multiple gestations</span> or other risk factors
                                        for preterm birth.</span> (<a href="#i4i_indications_id_7a40b457-9e12-43ef-906b-7f562bb6c622">1</a>)  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Administer intramuscularly at a dose
                                        of 250 mg (1 mL) once weekly</li>
<li>Begin treatment between 16 weeks, 0
                                        days and 20 weeks, 6 days of gestation</li>
<li>Continue administration once weekly
                                        until week 37 (through 36 weeks, 6 days) of gestation or
                                        delivery, whichever occurs first (<a href="#i4i_section_id_1fe619d8-d5a2-4d12-a9e3-0291e4867ff9">2.1</a>) </li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">5 mL multidose vial (250 mg/mL) contains 1250 mg
                                    hydroxyprogesterone caproate. (<a href="#i4i_dosage_form_strength_id_52aeae6a-a7db-475c-8517-b46e62aadff6">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Current or history of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or
                                        thromboembolic disorders (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
<li>Known or suspected breast cancer,
                                        other hormone-sensitive cancer, or history of these
                                        conditions (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
<li>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>
                                        unrelated to pregnancy (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy
                                            (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, benign or malignant, or
                                        active liver disease (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (<a href="#i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Thromboembolic disorders: Discontinue
                                        if <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> occurs (<a href="#i4i_section_id_1b17f7a2-32ff-4312-ad40-91598f3b0338">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>: Consider
                                        discontinuing if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur (<a href="#i4i_section_id_e8ed40b4-efeb-4004-a0dc-b48b40efc446">5.2</a>) </li>
<li>Decreased glucose tolerance: Monitor
                                        prediabetic and diabetic women receiving Makena (<a href="#i4i_section_id_aa57be1e-2fce-4c1d-9086-a2405b38bd66">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>: Monitor women with
                                        conditions that may be affected by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, such as
                                        preeclampsia, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, cardiac or renal dysfunction
                                            (<a href="#i4i_section_id_8e7a9f3d-4f4f-4fde-aad1-8f9a9956665a">5.4</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Monitor women with a
                                        history of clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; discontinue Makena if
                                        <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs (<a href="#i4i_section_id_6f3f6828-7aaa-4c34-ba2a-f51b0a9b4fba">5.5</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">
                                    Most common adverse reactions reported
                                        in ≥2% of subjects and at a higher rate in the Makena group
                                        than in the control group are <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
                                        [35%], <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> [17%], <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> [6%], <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> [5%]),
                                        <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (12%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (8%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (6%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                        (2%). (<a href="#i4i_section_id_ecad0ede-2f5c-4964-9b65-dd13b43be956">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
                                        contact Lumara Health at 1-877-411-2510 or FDA at
                                        1-800-FDA-1088 or <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"> Pregnancy: Controlled studies show no increase in
                                    congenital anomalies, including genital abnormalities in male or
                                    female infants, from exposure during pregnancy to
                                    hydroxyprogesterone caproate. (<a href="#i4i_pregnancy_id_0fa891af-35d1-4eac-b37d-7d8253b1cb26">8.1</a>) <br>  </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Thromboembolic Disorders</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Decrease in Glucose Tolerance</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Clinical Trial to Evaluate Reduction of Risk of Preterm
                                Birth</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Infant Follow-Up Safety Study</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7a40b457-9e12-43ef-906b-7f562bb6c622"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Makena is a progestin indicated to reduce the risk of preterm
                            birth in women with a singleton pregnancy who have a history of
                            singleton spontaneous preterm birth. The effectiveness of Makena is
                            based on improvement in the proportion of women who delivered &lt;37
                            weeks of gestation. There are no controlled trials demonstrating a
                            direct clinical benefit, such as improvement in neonatal mortality and
                            morbidity.</p>
<p><span class="Underline">Limitation of use</span>: While
                            there are many risk factors for preterm birth, safety and efficacy of
                            Makena has been demonstrated only in women with a prior spontaneous
                            singleton preterm birth. <span class="Bold">It is not intended
                                for use in women with <span class="product-label-link" type="condition" conceptid="432969" conceptname="Multiple pregnancy">multiple gestations</span> or other risk factors for
                                preterm birth.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1d0d2d32-cfec-4e0b-b384-5423284f335d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1fe619d8-d5a2-4d12-a9e3-0291e4867ff9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing</h2>
<ul class="Disc">
<li>Administer intramuscularly at a dose
                                        of 250 mg (1 mL) once weekly (every 7 days) by a healthcare
                                        provider</li>
<li>Begin treatment between 16 weeks, 0
                                        days and 20 weeks, 6 days of gestation</li>
<li>Continue administration once weekly
                                        until week 37 (through 36 weeks, 6 days) of gestation or
                                        delivery, whichever occurs first </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dd5abfe-68a9-475d-95b4-9466e1ae2294"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Administration</h2>
<p class="First">Parenteral drug products should be inspected visually for
                                    particulate matter and discoloration prior to administration,
                                    whenever solution and container permit. Makena is a clear,
                                    yellow solution. Do not use if solid particles appear or if the
                                    solution is cloudy.</p>
<p>Instructions for administration:</p>
<ol class="Arabic">
<li>Clean the vial top with an alcohol
                                        swab before use.</li>
<li>Draw up 1 mL of drug into a 3 mL
                                        syringe with an 18 gauge needle.</li>
<li>Change the needle to a 21 gauge 1 1/2
                                        inch needle.</li>
<li>After preparing the skin, inject in
                                        the upper outer quadrant of the gluteus maximus. The
                                        solution is viscous and oily. Slow injection (over one
                                        minute or longer) is recommended.</li>
<li>Applying pressure to the injection
                                        site may minimize <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</li>
</ol>
<p>Discard any unused product 5 weeks after first use.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_52aeae6a-a7db-475c-8517-b46e62aadff6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Makena (250 mg/mL) is a sterile solution of hydroxyprogesterone
                            caproate in castor oil for injection. Each 5 mL multidose vial
                            contains 1250 mg hydroxyprogesterone caproate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_516e9e2d-3fac-4fea-9685-5681af69b813"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Do not use Makena in women with any of the following conditions:</p>
<ul class="Disc">
<li>Current or history of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or
                                thromboembolic disorders</li>
<li>Known or suspected breast cancer, other
                                hormone-sensitive cancer, or history of these conditions</li>
<li>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>
                                unrelated to pregnancy</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, benign or malignant, or active
                                liver disease</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e10cec82-faed-4430-bd73-c561a25b7216"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b17f7a2-32ff-4312-ad40-91598f3b0338"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Thromboembolic Disorders</h2>
<p class="First">Discontinue Makena if an arterial or deep venous
                                    thrombotic or <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8ed40b4-efeb-4004-a0dc-b48b40efc446"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and
                                    <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, have been reported with use of Makena or with other
                                    products containing castor oil. Consider discontinuing the drug
                                    if such reactions occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa57be1e-2fce-4c1d-9086-a2405b38bd66"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Decrease in Glucose Tolerance</h2>
<p class="First">A decrease in glucose tolerance has been observed in some
                                    patients on progestin treatment. The mechanism of this decrease
                                    is not known. Carefully monitor prediabetic and diabetic women
                                    while they are receiving Makena.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e7a9f3d-4f4f-4fde-aad1-8f9a9956665a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Because progestational drugs may cause some degree of
                                    <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, carefully monitor women with conditions that
                                    might be influenced by this effect (e.g., preeclampsia,
                                    <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, cardiac or renal
                                dysfunction).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f3f6828-7aaa-4c34-ba2a-f51b0a9b4fba"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Monitor women who have a history of clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>
                                    and discontinue Makena if clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>
                                recurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f896d058-6e43-4d63-b37b-299aacb2dd11"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></h2>
<p class="First">Carefully monitor women who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> while
                                    receiving Makena and consider whether the benefit of use
                                    warrants continuation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d39b364c-655d-449b-a63f-c52cfe107959"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Carefully monitor women who develop <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> while
                                    receiving Makena and consider whether the benefit of use
                                    warrants continuation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_df45ce46-0d8e-464e-bca5-774cadf6db91"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">For the most serious adverse reactions to the use of progestins,
                            see <span class="Italics">Warnings and Precautions (<a href="#i4i_warnings_precautions_id_e10cec82-faed-4430-bd73-c561a25b7216">5</a>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ecad0ede-2f5c-4964-9b65-dd13b43be956"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
                                    varying conditions, adverse reaction rates observed in the
                                    clinical trials of a drug cannot be directly compared to the
                                    rates in the clinical trials of another drug and may not reflect
                                    the rates observed in practice.</p>
<p>In a vehicle (placebo)-controlled clinical trial of 463
                                    pregnant women at risk for spontaneous preterm delivery based on
                                    obstetrical history, 310 received 250 mg of Makena and 153
                                    received a vehicle formulation containing no drug by a weekly
                                    intramuscular injection beginning at 16 to 20 weeks of gestation
                                    and continuing until 37 weeks of gestation or delivery,
                                    whichever occurred first.<span class="Sup">1</span><span class="Italics"> [See Clinical Studies (<a href="#i4i_section_id_f6a9067a-1a3a-4d2d-b3cd-bd96265456bf">14.1</a>).] </span></p>
<p>Certain pregnancy-related fetal and maternal
                                    complications or events were numerically increased in the
                                    Makena-treated subjects as compared to control subjects,
                                    including <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span>, admission for preterm
                                    labor, preeclampsia or gestational <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, gestational
                                    <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> (Tables 1 and 2).</p>
<a name="_Refid_0bf52efd-8d1a-4da6-9171-508e0e5ed"></a><table width="100%">
<caption><span>Table 1 Selected Fetal Complications</span></caption>
<col width="42%">
<col width="29%">
<col width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top">
<span class="Sup">1</span> N = Total number of
                                                subjects enrolled prior to 20 weeks 0
                                                  days<br><span class="Sup">2</span> N = Total number of
                                                subjects at risk ≥ 20 weeks</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First"><span class="Bold">Pregnancy
                                                  Complication</span></p></td>
<td class="Rrule Toprule" align="center"><p class="First"><span class="Bold">Makena</span></p></td>
<td class="Rrule Toprule" align="center"><p class="First"><span class="Bold">Control</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">n/N</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Miscarriage</span> (&lt; 20
                                                  weeks)<span class="Sup">1</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5/209</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0/107</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">Stillbirth</span> (≥ 20
                                                weeks)<span class="Sup">2</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6/305</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2/153</p></td>
</tr>
</tbody>
</table>
<a name="_Refid_94cd60ed-6381-4599-a82c-ceb4ce20d"></a><table width="100%">
<caption><span>Table 2 Selected Maternal Complications</span></caption>
<col width="46%">
<col width="28%">
<col width="27%">
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top">
<span class="Sup">1</span> Other than delivery
                                                admission.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Pregnancy
                                                  Complication</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Makena</span><br><span class="Bold">N=310</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Control</span><br><span class="Bold">N=153</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Admission for preterm
                                                labor<span class="Sup">1</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 16.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 13.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Preeclampsia or gestational
                                                <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 8.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">Gestational diabetes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 5.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 4.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 3.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 1.3</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Common Adverse
                                    Reactions:</span></p>
<p>The most common adverse reaction was <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>,
                                    which was reported after at least one injection by 34.8% of the
                                    Makena group and 32.7% of the control group. Table 3 lists
                                    adverse reactions that occurred in ≥2% of subjects and at a
                                    higher rate in the Makena group than in the control group.</p>
<a name="_Refid_71bdf40c-33aa-4f4b-ab17-5566b3dd1"></a><table width="100%">
<caption><span>Table 3 Adverse Reactions Occurring in ≥ 2% of
                                        Makena-Treated Subjects and at a Higher Rate than Control
                                        Subjects</span></caption>
<col width="47%">
<col width="27%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First"> </p>
<p><span class="Bold">Preferred Term
                                                  </span></p>
</td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Makena</span><br><span class="Bold">N=310</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Control</span><br><span class="Bold">N=153</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">34.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">32.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Injection site swelling  </p></td>
<td class="Botrule Rrule" align="center"><p class="First">17.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 7.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 7.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 5.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 5.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 5.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Injection site <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 4.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 2.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 2.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 0.7</p></td>
</tr>
</tbody>
</table>
<p>In the clinical trial, 2.2% of subjects receiving Makena
                                    were reported as discontinuing therapy due to adverse reactions
                                    compared to 2.6% of control subjects. The most common adverse
                                    reactions that led to discontinuation in both groups were
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (1% each).</p>
<p><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolus</span> in one subject and injection site
                                    <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> in another subject were reported as serious adverse
                                    reactions in Makena-treated subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b6355a0-0ed0-46a0-8172-7e68870fa2c7"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified
                                    during postapproval use of Makena. Because these reactions are
                                    reported voluntarily from a population of uncertain size, it is
                                    not always possible to reliably estimate their frequency or
                                    establish a causal relationship to drug exposure.</p>
<ul class="Disc">
<li>
<span class="Italics">Body as a
                                            whole</span>: Local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>
                                        (including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, irritation,
                                        <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, warmth); <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; hot
                                        flashes/flushes</li>
<li>
<span class="Italics">Digestive
                                            disorders</span>: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></li>
<li>
<span class="Italics">Nervous
                                            system disorders</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>
<span class="Italics">Pregnancy, puerperium and perinatal
                                        conditions:</span> <span class="product-label-link" type="condition" conceptid="436740" conceptname="Cervical incompetence">Cervical incompetence</span>, premature
                                        rupture of membranes</li>
<li>
<span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span>
                                        Cervical dilation, shortened cervix</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span></span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, chest
                                        <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></li>
<li>
<span class="Italics">Skin</span>: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_72b22c72-8b9a-4e24-8f2b-8ff5cc610d38"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro</span> drug-drug
                            interaction studies were conducted with Makena. <span class="Italics">[See Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a54773f7-8404-4310-85e3-e06fdb3066b4">12.3</a>).]</span> No <span class="Italics">in
                                vivo</span> drug-drug interaction studies were conducted with
                            Makena.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_1a02bb79-28c6-4b22-8f66-3bf879158cda"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_0fa891af-35d1-4eac-b37d-7d8253b1cb26"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category B:</span></span> There are no adequate and well-controlled studies of
                                    Makena use in women during the <span class="Underline">first trimester</span> of pregnancy. Data from a vehicle
                                    (placebo)-controlled clinical trial of 310 pregnant women who
                                    received Makena at weekly doses of 250 mg by intramuscular
                                    injection in their second and third trimesters<span class="Sup">1</span>, as
                                    well as long-term (2-5 years) follow-up safety data on 194 of
                                    their infants <span class="Sup">2</span>, did not demonstrate any teratogenic
                                    risks to infants from in utero exposure to Makena. </p>
<p>Reproduction studies have been performed in mice and rats
                                    at doses up to 95 and 5, respectively, times the human dose and
                                    have revealed no evidence of impaired fertility or harm to the
                                    fetus due to Makena.</p>
<p>Makena administration produced embryolethality in rhesus
                                    monkeys but not in cynomolgus monkeys exposed to 1 and 10 times
                                    the human dose equivalent every 7 days between days 20 and 146
                                    of gestation. There were no teratogenic effects in either
                                    species.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_3993527e-71e5-419a-8dce-a66f26bf2c10"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Makena is not intended for use to stop active preterm
                                    labor. The effect of Makena in active labor is
                                unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_de2a8a97-8c14-496b-8cf1-d995cc021d5e"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Discontinue Makena at 37 weeks of gestation or upon
                                    delivery. Detectable amounts of progestins have been identified
                                    in the milk of mothers receiving progestin treatment. Many
                                    studies have found no adverse effects of progestins on
                                    breastfeeding performance, or on the health, growth, or
                                    development of the infant</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_57f4fc1a-162f-438a-9ec7-0085d647b687"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"> Makena is not indicated for use in children. Safety and
                                    effectiveness in pediatric patients less than 16 years of age
                                    have not been established. A small number of women under age 18
                                    years were studied; safety and efficacy are expected to be the
                                    same in women aged 16 years and above as for users 18 years and
                                    older. <span class="Italics">[See Clinical Studies
                                            (<a href="#i4i_clinical_studies_id_1ecff9cb-f468-41a4-b05e-31a141b9edde">14</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_264b8154-5cff-4b11-82bb-60897100ab2c"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Makena is not intended for use in postmenopausal women.
                                    Safety and effectiveness in postmenopausal women have not been
                                    established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_656cccea-9c08-40a9-aef1-7b7242c4969f"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No studies have been conducted to examine the
                                    pharmacokinetics of Makena in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
                                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7844d543-792b-4e5c-b76a-40609e5d6ca2"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No studies have been conducted to examine the
                                    pharmacokinetics of Makena in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
                                    Makena is extensively metabolized and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may
                                    reduce the elimination of Makena.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_9d3ea267-ae57-4092-8c05-9164ebcde9f2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There have been no reports of adverse events associated with
                            overdosage of Makena in clinical trials. In the case of overdosage, the
                            patient should be treated symptomatically.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_7c26d5c8-a1bd-4a28-b812-5c38b81deac7"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active pharmaceutical ingredient in Makena is
                            hydroxyprogesterone caproate.</p>
<p>The chemical name for hydroxyprogesterone caproate is
                            pregn-4-ene-3,20-dione, 17[(1-oxohexyl)oxy]. It has an empirical formula
                            of C<span class="Sub">27</span>H<span class="Sub">40</span>O<span class="Sub">4</span> and a molecular weight of
                            428.60. Hydroxyprogesterone caproate exists as white to practically
                            white crystals or powder with a melting point of 120°-124°C.</p>
<p>The structural formula is:</p>
<p><a name="id718"></a><img alt="Chemical Structure for Hydroxyprogesterone Caproate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1998c1d-8337-4f00-8dcb-af3b54d39b77&amp;name=makena-01.jpg"></p>
<p>Makena is a clear, yellow, sterile, non-pyrogenic solution for
                            intramuscular injection. Each 5 mL multidose vial
                            contains hydroxyprogesterone caproate USP, 250 mg/mL (25% w/v), in
                            castor oil USP (28.6% v/v) and benzyl benzoate USP (46% v/v) with the
                            preservative benzyl alcohol NF (2% v/v).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9b35368a-9536-48bb-a325-e8aaaf9ac6c9"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_3322e347-ad5d-4997-ab36-d1c1672c4fa4"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Hydroxyprogesterone caproate is a synthetic progestin.
                                    The mechanism by which hydroxyprogesterone caproate reduces the
                                    risk of recurrent preterm birth is not known.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_348c94bd-2f4b-4d20-ba3e-ab8a966918f8"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">No specific pharmacodynamic studies were conducted with
                                    Makena.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a54773f7-8404-4310-85e3-e06fdb3066b4"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption:</span> Peak
                                    serum levels of hydroxyprogesterone caproate appeared after 3-7
                                    days in non-pregnant female subjects following a single
                                    intramuscular injection of 1000 mg hydroxyprogesterone caproate.
                                    Based on pharmacokinetic analysis of five non-pregnant female
                                    subjects who received a single intramuscular administration of
                                    1000 mg hydroxyprogesterone caproate, the mean (±SD)
                                    C<span class="Sub">max</span> is estimated to be 27.8 (±5.3) ng/mL, and the
                                        T<span class="Sub">max</span> is estimated to be 4.6 (±1.7) days. The
                                    elimination half-life of hydroxyprogesterone caproate was 7.8
                                    (±3.0) days. Once-weekly intramuscular administration of 1000 mg
                                    hydroxyprogesterone caproate to non-pregnant women resulted in
                                    trough concentration of 60.0 (±14) ng/mL after 13 weeks. The
                                    pharmacokinetics of the 250 mg dose of hydroxyprogesterone
                                    caproate has not been evaluated.</p>
<p><span class="Italics">Distribution:</span>
                                    Hydroxyprogesterone caproate binds extensively to plasma
                                    proteins including albumin and corticosteroid binding globulins.</p>
<p><span class="Italics">Metabolism:</span> In
                                    vitro studies have shown that hydroxyprogesterone caproate can
                                    be metabolized by human hepatocytes, both by phase I and phase
                                    II reactions. Hydroxyprogesterone caproate undergoes extensive
                                    reduction, hydroxylation and conjugation. The conjugated
                                    metabolites include sulfated, glucuronidated and acetylated
                                    products. In vitro data indicate that the metabolism of
                                    hydroxyprogesterone caproate is predominantly mediated by CYP3A4
                                    and CYP3A5. The in vitro data indicate that the caproate group
                                    is retained during metabolism of hydroxyprogesterone caproate.</p>
<p><span class="Italics">Excretion:</span> Both
                                    conjugated metabolites and free steroids are excreted in the
                                    urine and feces, with the conjugated metabolites being
                                    prominent. Following intramuscular administration to pregnant
                                    women at 10-12 weeks gestation, approximately 50% of a dose was
                                    recovered in the feces and approximately 30% recovered in the
                                    urine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_specific_populations_duplicate_id_1c3fac91-f1b2-4492-b515-b10c220d55d3"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First"><span class="Italics">Renal
                                            Impairment:</span> The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on
                                            the pharmacokinetics of Makena has not been evaluated.</p>
<p><span class="Italics">Hepatic
                                            Impairment:</span> The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>
                                            on the pharmacokinetics of Makena has not been
                                            evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_drug_interaction_id_16d208b8-396e-42c1-9547-c05118e2bbe5"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Drug Interactions</span></h3>
<p class="First"><span class="Italics">Cytochrome P450
                                                (CYP) enzymes: </span>An <span class="Italics">in vitro</span> inhibition
                                            study using human liver microsomes and CYP
                                            isoform-selective substrates indicated that
                                            hydroxyprogesterone caproate increased the metabolic
                                            rate of CYP1A2, CYP2A6, and CYP2B6 by approximately 80%,
                                            150%, and 80%, respectively. However, in another
                                                <span class="Italics">in vitro</span>
                                            study using human hepatocytes under conditions where the
                                            prototypical inducers or inhibitors caused the
                                            anticipated increases or decreases in CYP enzyme
                                            activities, hydroxyprogesterone caproate did not induce
                                            or inhibit CYP1A2, CYP2A6, or CYP2B6 activity. Overall,
                                            the findings indicate that hydroxyprogesterone caproate
                                            has minimal potential for CYP1A2, CYP2A6, and CYP2B6
                                            related drug-drug interactions at the clinically
                                            relevant concentrations.</p>
<p><span class="Italics">In vitro</span>
                                            data indicated that therapeutic concentration of
                                            hydroxyprogesterone caproate is not likely to inhibit
                                            the activity of CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1,
                                            and CYP3A4.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_820253dc-0c5b-4927-9416-a3feb41b00d6"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8a272f21-608d-45ef-bdd9-8fc7519ba13f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Hydroxyprogesterone caproate has not been adequately
                                    evaluated for carcinogenicity.</p>
<p>No reproductive or developmental toxicity or impaired
                                    fertility was observed in a multigenerational study in rats.
                                    Makena administered intramuscularly, at gestational exposures up
                                    to 5 times the recommended human dose, had no adverse effects on
                                    the parental (F<span class="Sub">0</span>) dams, their developing offspring
                                        (F<span class="Sub">1</span>), or the latter offspring's ability to
                                    produce a viable, normal second (F<span class="Sub">2</span>)
                                generation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_1ecff9cb-f468-41a4-b05e-31a141b9edde"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6a9067a-1a3a-4d2d-b3cd-bd96265456bf"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Clinical Trial to Evaluate Reduction of Risk of Preterm
                                Birth</h2>
<p class="First"> In a multicenter, randomized, double-blind, vehicle
                                    (placebo)-controlled clinical trial, the safety and
                                    effectiveness of Makena for the reduction of the risk of
                                    spontaneous preterm birth was studied in women with a singleton
                                    pregnancy (age 16 to 43 years) who had a documented history of
                                    singleton spontaneous preterm birth (defined as delivery at less
                                    than 37 weeks of gestation following spontaneous preterm labor
                                    or <span class="product-label-link" type="condition" conceptid="194702" conceptname="Premature rupture of membranes">premature rupture of membranes</span>).<span class="Sup">1</span> At the time of
                                    randomization (between 16 weeks, 0 days and 20 weeks, 6 days of
                                    gestation), an ultrasound examination had confirmed gestational
                                    age and no known fetal anomaly. Women were excluded for prior
                                    progesterone treatment or heparin therapy during the current
                                    pregnancy, a history of thromboembolic disease, or
                                    maternal/obstetrical complications (such as current or planned
                                    cerclage, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> requiring medication, or a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>
                                    disorder). </p>
<p> A total of 463 pregnant women were randomized to receive
                                    either Makena (N=310) or vehicle (N=153) at a dose of 250 mg
                                    administered weekly by intramuscular injection starting between
                                    16 weeks, 0 days and 20 weeks, 6 days of gestation, and
                                    continuing until 37 weeks of gestation or delivery. Demographics
                                    of the Makena-treated women were similar to those in the control
                                    group, and included: 59.0% Black, 25.5% Caucasian, 13.9%
                                    Hispanic and 0.6% Asian. The mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index was 26.9
                                        kg/m<span class="Sup">2</span>. </p>
<p> The proportions of women in each treatment arm who
                                    delivered at &lt;37 (the primary study endpoint),
                                    &lt;35, and &lt;32 weeks of gestation are displayed in
                                    Table 4.</p>
<a name="_Refid_c27c5458-4e41-4f85-a952-b477f858b"></a><table width="100%">
<caption><span>Table 4 Proportion of Subjects Delivering at &lt;
                                        37, &lt; 35  and &lt; 32 Weeks Gestational Age (ITT
                                        Population)</span></caption>
<col width="23%">
<col width="23%">
<col width="23%">
<col width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top">
<span class="Sup">1</span> Four Makena-treated
                                                subjects were lost to follow-up. They were counted
                                                as deliveries at their gestational ages at time of
                                                last contact (18<span class="Sup">4</span>, 22<span class="Sup">0</span>,
                                                  34<span class="Sup">3</span> and 36<span class="Sup">4</span>
                                                  weeks).<br><span class="Sup">2</span> Adjusted for interim
                                                analysis.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">Delivery</span></p>
<p><span class="Bold">Outcome</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Makena<span class="Sup">1</span></span><br><span class="Bold">(N=310)</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Control</span><br><span class="Bold">(N=153)</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment difference
                                                  and </span><br><span class="Bold">95% Confidence
                                                  Interval<span class="Sup">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&lt;37  weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">37.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">54.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-17.8% [-28.0%, -7.4%]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&lt;35  weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">21.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">30.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-9.4% [-19.0%, -0.4%]</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">&lt;32 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-7.7% [-16.1%, -0.3%]</p></td>
</tr>
</tbody>
</table>
<p>Compared to controls, treatment with Makena reduced the
                                    proportion of women who delivered preterm at &lt;37 weeks.
                                    The proportions of women delivering at &lt;35 and &lt;
                                    32 weeks also were lower among women treated with Makena. The
                                    upper bounds of the confidence intervals for the treatment
                                    difference at &lt; 35 and &lt;32 weeks were close to
                                    zero. Inclusion of zero in a confidence interval would indicate
                                    the treatment difference is not statistically significant.
                                    Compared to the other gestational ages evaluated, the number of
                                    preterm births at &lt;32 weeks was limited. </p>
<p>After adjusting for time in the study, 7.5% of
                                    Makena-treated subjects delivered prior to 25 weeks compared to
                                    4.7% of control subjects; see Figure 1.</p>
<p><span class="Bold">Figure 1 Proportion of Women Remaining Pregnant as a Function of Gestational Age</span></p>
<p><a name="id878"></a><img alt="Figure 1 Proportion of Women Remaining Pregnant as a
                                        Function of Gestational Age" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1998c1d-8337-4f00-8dcb-af3b54d39b77&amp;name=makena-02.jpg"></p>
<p>The rates of fetal losses and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in each treatment
                                    arm are displayed in Table 5. Due to the higher rate of
                                    <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriages</span> and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> in the Makena arm, there was no
                                    overall survival difference demonstrated in this clinical trial.</p>
<a name="_Refid_7def6426-fd1a-4e72-b9e4-de6cf1e4c"></a><table width="100%">
<caption><span>Table 5 Fetal Losses and Neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span></span></caption>
<col width="41%">
<col width="29%">
<col width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top">
<span class="Sup">A </span>Four of the 310
                                                Makena-treated subjects were lost to follow-up and
                                                <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> or neonatal status could not be
                                                  determined<br><span class="Sup">B</span> Percentages are
                                                based on the number of enrolled subjects and not
                                                adjusted for time on drug<br><span class="Sup">C</span>
                                                Percentage adjusted for the number of at risk
                                                subjects (n=209 for Makena, n=107 for control)
                                                enrolled at &lt;20 weeks gestation.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First"> </p>
<p><span class="Bold">Complication</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Makena</span><br><span class="Bold">N=306<span class="Sup"> A</span></span><br><span class="Bold">n (%)
                                                  <span class="Sup">B</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Control</span><br><span class="Bold">N=153</span><br><span class="Bold">n (%)
                                                  <span class="Sup">B</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Miscarriages</span> &lt;20 weeks
                                                  gestation<span class="Sup"> C</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (2.4)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">Stillbirth</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6 (2.0)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (1.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">      <span class="Italics">Antepartum <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Italics">5 (1.6)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Italics">1 (0.6)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">      <span class="Italics">Intrapartum
                                                <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Italics">1 (0.3)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Italics">1 (0.6)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8 (2.6)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9 (5.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">19 (6.2)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">11 (7.2)</span></p></td>
</tr>
</tbody>
</table>
<p>A composite neonatal morbidity/mortality index evaluated
                                    adverse outcomes in livebirths. It was based on the number of
                                    neonates who died or experienced <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome,
                                    <span class="product-label-link" type="condition" conceptid="4283942" conceptname="Bronchopulmonary dysplasia of newborn">bronchopulmonary dysplasia</span>, grade 3 or 4 intraventricular
                                    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, proven <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, or <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.
                                    Although the proportion of neonates who experienced 1 or more
                                    events was numerically lower in the Makena arm (11.9% vs.
                                    17.2%), the number of adverse outcomes was limited and the
                                    difference between arms was not statistically
                                significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0ace3e9-9f94-42f4-bd3c-953cb484e2e8"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Infant Follow-Up Safety Study</h2>
<p class="First">Infants born to women enrolled in this study, and who
                                    survived to be discharged from the nursery, were eligible for
                                    participation in a follow-up safety study. Of 348 eligible
                                    offspring, 79.9% enrolled: 194 children of Makena-treated women
                                    and 84 children of control subjects. The primary endpoint was
                                    the score on the Ages &amp; Stages Questionnaire (ASQ),
                                    which evaluates communication, gross motor, fine motor, problem
                                    solving, and personal/social parameters. The proportion of
                                    children whose scores met the screening threshold for
                                    <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span> in each developmental domain was similar for
                                    each treatment group.<span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_988eb45d-7780-4eb5-b6e0-8371e69339ec"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First"><span class="Sup">1</span>Meis PJ, Klebanoff M, Thom E, et al. Prevention of
                            recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
                                <span class="Italics">N Engl J Med.
                            </span>2003;348(24):2379-85.</p>
<p><span class="Sup">2</span>Northen A, Norman G, Anderson K, et al. Follow-up of
                            children exposed in utero to 17 alpha-hydroxyprogesterone caproate.
                                <span class="Italics">Obstet &amp; Gynecol.
                            </span>2007;110:865-872.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2844e92d-4c56-4604-b7a6-95a921d0de89"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Makena (NDC 64011-243-01) is supplied as 5 mL of a sterile
                            solution in a multidose glass vial.</p>
<p>Each 5 mL vial contains hydroxyprogesterone caproate USP, 250
                            mg/mL (25% w/v), in castor oil USP (28.6% v/v) and benzyl benzoate USP
                            (46% v/v) with the preservative benzyl alcohol NF (2% v/v).</p>
<p>Single unit carton: Contains one 5 mL multidose vial of Makena
                            (250 mg/mL) containing 1250 mg of hydroxyprogesterone caproate.</p>
<p>Store at controlled room temperature [15°-30°C (59°-86°F)]. Use
                            within 5 weeks after first use.</p>
<p>Caution: Protect vial from light. Store vial in its box. Store
                            upright.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_49238909-b5ca-4e2b-9a82-2c99e2dc6773"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information).</p>
<p>Counsel patients that Makena injections may cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness,
                            <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>. Inform the patient to contact her
                            physician if she notices increased <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> over time, oozing of blood
                            or fluid, or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> at the injection site <span class="Italics"> [see Adverse Reactions (<a href="#i4i_section_id_ecad0ede-2f5c-4964-9b65-dd13b43be956">6.1</a>)] </span>. </p>
<p>Manufactured by:     Hospira, Inc.<br>                               McPherson, KS 67460</p>
<p>Marketed by:           Lumara Health Inc.<br>                               A division of AMAG Pharmaceuticals, Inc.<br>                               Waltham, MA 02451</p>
<p>P10072-3<br>02/2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_a8846245-a54e-4d2b-98bc-440a51bb9fb3"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Makena (mah-KEE-na)</span><br><span class="Bold">(hydroxyprogesterone caproate injection) 250
                                mg/mL </span></p>
<p>Read this Patient Information Leaflet before you receive Makena.
                            There may be new information. This information does not take the place
                            of talking to your healthcare provider about your medical condition or
                            treatment.</p>
<p><span class="Bold">What is Makena?</span></p>
<p>Makena is a prescription hormone medicine (progestin) used in
                            women who are pregnant and who have delivered a baby too early (preterm)
                            in the past. Makena is used in these women to help lower the risk of
                            having a preterm baby again.</p>
<p>Makena is for women who:</p>
<ul class="Disc">
<li>Are pregnant with one baby</li>
<li>Have had a preterm delivery of one baby in the
                                past</li>
</ul>
<p><span class="Bold">How well does Makena work?</span></p>
<p>Makena was studied in women who were at risk for having a preterm
                            baby because they had previously given birth to a preterm baby. In the
                            main study, about 37 of 100 women who received Makena gave birth preterm
                            (before 37 weeks of pregnancy), compared to about 55 of 100 women who
                            did not receive Makena. Another study of Makena is going on to see
                            whether Makena reduces the number of babies who have serious problems
                            shortly after birth or who die.</p>
<p>It is not known whether Makena is safe and effective in women who
                            have other risk factors for preterm birth.</p>
<p>It is not known whether Makena is safe and effective in women
                            less than 16 years old.</p>
<p>Makena is not intended for use to stop active preterm labor.</p>
<p><span class="Bold">Who should not receive Makena?</span></p>
<p>Makena should not be used if you:</p>
<ul class="Disc">
<li>Have now or have had a history of blood clots
                                or other blood clotting problems</li>
<li>Have now or have had a history of breast
                                cancer or other hormone-sensitive cancers</li>
<li>Have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> not related to
                                your current pregnancy</li>
<li>Have yellowing of your skin due to liver
                                problems during your pregnancy </li>
<li>Have liver problems, including <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></li>
<li>Have uncontrolled high blood pressure</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider
                                before receiving Makena?</span></p>
<p>Before you receive Makena, tell your healthcare provider if you
                            have:</p>
<ul class="Disc">
<li>An <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to hydroxyprogesterone caproate,
                                castor oil, or any of the other ingredients in Makena. See the end
                                of this patient leaflet for a complete list of the ingredients in
                                Makena.</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> or prediabetes</li>
<li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></li>
<li>Heart problems</li>
<li>Kidney problems</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></li>
<li>High blood pressure</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take,
                            including prescription and non-prescription medicines, vitamins, and
                            herbal supplements.</p>
<p>Makena may affect the way other medicines work, and other
                            medicines may affect how Makena works.</p>
<p>Know the medicines you take. Keep a list of them to show your
                            healthcare provider and pharmacist when you get a new medication. </p>
<p><span class="Bold">How should I receive Makena?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Do not give yourself
                                    Makena injections.</span> A healthcare professional will give
                                you the Makena injection into your hip area (upper outer area of the
                                buttocks) once a week (every 7 days). </li>
<li>You will <span class="Bold">start</span> receiving Makena injections anytime from 16 weeks
                                and 0 days of your pregnancy up to 20 weeks and 6 days of your
                                pregnancy. </li>
<li>You will continue to receive Makena injections
                                once weekly until week 37 of your pregnancy or when your baby is
                                delivered, whichever happens first.</li>
</ul>
<p>Makena comes in ready-to-use vials. There are 5 doses
                            of medicine in each vial. Your healthcare professional should give you
                            only <span class="Bold">one dose </span> (1 mL) of Makena as
                            prescribed each week. </p>
<p><span class="Bold">Makena should
                                be used within 5 weeks after the first use.</span></p>
<p>It is very important that you do not miss a dose of Makena and
                            that you continue to receive the medicine once a week. If you miss a
                            dose, talk to your healthcare provider for specific directions on how to
                            get back on schedule.</p>
<p><span class="Bold">What are the possible side effects of
                            Makena?</span></p>
<p>Makena may cause serious side effects, including:</p>
<ul class="Disc">
<li>
<span class="Bold">Blood
                                clots.</span> Symptoms of a blood clot may include: <ul class="Circle">
<li>Leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span> in your leg</li>
<li>A spot on your leg that is warm to
                                        touch</li>
<li><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Leg pain</span> that worsens when you bend
                                        your foot</li>
</ul>
</li>
<li>
<span class="Bold">Allergic
                                reactions.</span> Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include:
                                    <ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the face</li>
</ul>
<br>Call your healthcare provider right away if
                                you get any of the symptoms above.<br><br>
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span></li>
<li><span class="Bold">Yellowing of your skin and the whites of
                                    your eyes</span></li>
</ul>
<p>The most common side effects of Makena include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or a hard
                                bump at the injection site</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
</ul>
<p>Call your healthcare provider if you have the following at your
                            injection site:</p>
<ul class="Disc">
<li>Increased <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> over time</li>
<li>Oozing of blood or fluid</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that
                            bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Makena. For more
                            information, ask your healthcare provider or pharmacist.</p>
<p>In a clinical study, certain complications or events associated
                            with pregnancy occurred more often in women who received Makena compared
                            to women who did not receive Makena, including:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Miscarriage</span> (pregnancy loss before 20 weeks of
                                pregnancy)</li>
<li><span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">Stillbirth</span> (<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> occurring after the
                                20th week of pregnancy)</li>
<li>Hospital admission for preterm labor</li>
<li>Preeclampsia (high blood pressure and too much
                                protein in your urine)</li>
<li>Gestational <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (high blood pressure
                                caused by pregnancy)</li>
<li><span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">Gestational diabetes</span></li>
<li><span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> (low amniotic fluid
                            levels)</li>
</ul>
<p>Call your healthcare provider for medical advice about side
                            effects or pregnancy complications. You may report side effects to FDA
                            at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Makena?</span></p>
<ul class="Disc">
<li>Store Makena at room temperature (59° to 86°F
                                or 15° to 30°C)</li>
<li>Store Makena in the original box to protect it
                                from light</li>
<li>Store the Makena box upright</li>
<li>Makena 5 mL multidose vials should be used
                                within 5 weeks after first use.</li>
<li><span class="Bold">Keep Makena out of the reach of
                                children</span></li>
</ul>
<p><span class="Bold">General information about the safe and
                                effective use of Makena.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
                            mentioned in the Patient Information Leaflets. Do not take Makena for
                            conditions for which it was not prescribed. Do not give Makena to other
                            people, even if they have the same condition you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about
                            Makena. If you would like more information, talk with your healthcare
                            provider. You can ask for information about Makena that is written for
                            healthcare professionals.</p>
<p>For more information, go to www.makena.com or call Lumara Health
                            Customer Service at the toll free number 1-877-411-2510.</p>
<p>To refill a prescription or to check on prescription status, call
                            the Makena Care Connection at the toll free number 1-800-847-3418.</p>
<p><span class="Bold">What are the ingredients in Makena?</span></p>
<p>Active ingredient: hydroxyprogesterone caproate</p>
<p>Inactive ingredients: castor oil and benzyl benzoate. 5 mL
                            multidose vials also contain benzyl alcohol (a
                        preservative).</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7a86d122-d5e6-4452-9349-fea64ea8094c"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Carton Label</h1>
<p class="First">NDC 64011-243-01</p>
<p><span class="Bold">Makena<span class="Sup">®</span></span><br><span class="Bold">hydroxyprogesterone caproate injection</span></p>
<p>1250 mg/5 mL<br>(250 mg/mL)</p>
<p><span class="Bold">FOR INTRAMUSCULAR USE</span></p>
<p><span class="Bold">5 mL multidose vial</span><br><span class="Bold">R<span class="Sub">x</span> ONLY</span></p>
<p><span class="Bold">Store at controlled room temperature</span><br>15°-30°C (59°-86°F).</p>
<p><span class="Bold">Caution: Protect from light.</span><br>Store vial in its box. Store upright. Use within 5 weeks after first use.</p>
<p>Each mL contains: hydroxyprogesterone caproate 250 mg, benzyl benzoate 46%, castor oil 28.6%, and benzyl alcohol 2%, as preservative.</p>
<p><span class="Bold">See package insert for full prescribing and patient information.</span></p>
<p><span class="Bold">Lumara Health™</span><br>A division of AMAG Pharmaceuticals</p>
<p>P8009-1
                            <br>02/15</p>
<p>Marketed by
                            <br>Lumara Health, a division of AMAG Pharmaceuticals,
                            <br>Waltham, MA 02451</p>
<br><p><a name="id112718424"></a><img alt="5 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1998c1d-8337-4f00-8dcb-af3b54d39b77&amp;name=makena-03.jpg"></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAKENA 		
					</strong><br><span class="contentTableReg">hydroxyprogesterone caproate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64011-243</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROXYPROGESTERONE CAPROATE</strong> (HYDROXYPROGESTERONE) </td>
<td class="formItem">HYDROXYPROGESTERONE CAPROATE</td>
<td class="formItem">250 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem">277.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL BENZOATE</strong></td>
<td class="formItem">514.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">21.92 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64011-243-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021945</td>
<td class="formItem">02/03/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lumara Health Inc.
							(006291405)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030606222</td>
<td class="formItem">MANUFACTURE(64011-243), ANALYSIS(64011-243)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Pharmaceutical Solutions, LLC</td>
<td class="formItem"></td>
<td class="formItem">604719430</td>
<td class="formItem">MANUFACTURE(64011-243), ANALYSIS(64011-243)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>443b541b-63f5-41c5-a04b-230e33b19ba5</div>
<div>Set id: a1998c1d-8337-4f00-8dcb-af3b54d39b77</div>
<div>Version: 8</div>
<div>Effective Time: 20150228</div>
</div>
</div> <div class="DistributorName">Lumara Health Inc.</div></p>
</body></html>
